The Robert H. Lurie Cancer Center (Lurie Cancer Center) has developed a comprehensive system of protocol review and oversight called the Clinical Protocol Scientific Review and Monitoring System (CPSRMS). This system is comprised of three distinct committees that work collaboratively to provide oversight of all aspects of clinical research conducted at the Lurie Cancer Center. These committees include: the Scientific Review Committee (SRC), the Data Monitoring Committee (DMC), and the Clinical Trial Audit Committee (CTAC). Each committee includes a Chair and/or Co-chair, but the CPSRMS overall is directed by the Associate Director for Clinical Investigations ofthe Lurie Cancer Center, Dr. Al B. Benson. This position is appointed by and reports to Dr. Steven Rosen, the Director ofthe Lurie Cancer Center. The three committees work in conjunction to form a robust system designed to ensure that research conducted at our center has scientific merit and meets the goals and priorities of the center, that clinical trial progress is maintained, and that patient safety and data integrity are maintained for our Northwestern University investigator-initiated trials (NU IITs). The CPSRMS committee responsible for Protocol Review and Monitoring (PRMS) is the SRC. The SRC is charged with the responsibility of evaluating all new and ongoing clinical research protocols for scientific merit, institutional priority and ongoing progress. The committee is a multidisciplinary committee that meets bimonthly to evaluate protocols. All cancer-relevant research studies conducted within the Lurie Cancer Center fall under the purview of this committee and require a level of review. Any faculty member within NU and all Lurie Cancer Center members are required to submit cancer-relevant clinical research protocols to the SRC for review. Protocols are classified into four types: institutional, external peer-reviewed, national/cooperative group, and industrial trials. The different types of protocols undergo different levels of review by the SRC. Any study that is reviewed and approved by an NCI approved peer-review committee (national trials and external peer-reviewed) is exempt from initial and ongoing SRC review for scientific merit. These studies are reviewed administratively for prioritization, and are reviewed annually for progress. All other studies (institutional and industrial) require initial and ongoing SRC review for scientific merit, and also are reviewed for prioritization and progress. Importantly, the NU Institutional Review Board (IRB) requires Lurie Cancer Center endorsement for all cancer-relevant protocols prior to IRB review, therefore ensuring the SRC review requirements have been appropriately met. The administrative support for SRC is coordinated through the Clinical Research Office (CRO).

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA060553-20
Application #
8761079
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2014-08-01
Budget End
2015-07-31
Support Year
20
Fiscal Year
2014
Total Cost
$129,458
Indirect Cost
$46,268
Name
Northwestern University at Chicago
Department
Type
DUNS #
005436803
City
Chicago
State
IL
Country
United States
Zip Code
60611
Joyce, Brian T; Zheng, Yinan; Zhang, Zhou et al. (2018) miRNA-Processing Gene Methylation and Cancer Risk. Cancer Epidemiol Biomarkers Prev 27:550-557
Kenney, Grace E; Dassama, Laura M K; Pandelia, Maria-Eirini et al. (2018) The biosynthesis of methanobactin. Science 359:1411-1416
Symes, Yael R; Barrington, Clare; Austin, Jane et al. (2018) Advice to patients undergoing stem cell transplant: Content analysis of survivor peer support narratives. J Health Psychol 23:818-828
Chu, Lan H; Indramohan, Mohanalaxmi; Ratsimandresy, Rojo A et al. (2018) The oxidized phospholipid oxPAPC protects from septic shock by targeting the non-canonical inflammasome in macrophages. Nat Commun 9:996
Ugolkov, Andrey V; Bondarenko, Gennadiy I; Dubrovskyi, Oleksii et al. (2018) 9-ING-41, a small-molecule glycogen synthase kinase-3 inhibitor, is active in neuroblastoma. Anticancer Drugs 29:717-724
Lewis, Phillip L; Green, Richard M; Shah, Ramille N (2018) 3D-printed gelatin scaffolds of differing pore geometry modulate hepatocyte function and gene expression. Acta Biomater 69:63-70
Volk, Andrew; Liang, Kaiwei; Suraneni, Praveen et al. (2018) A CHAF1B-Dependent Molecular Switch in Hematopoiesis and Leukemia Pathogenesis. Cancer Cell 34:707-723.e7
Chen, Charlotte H; Palmer, Liam C; Stupp, Samuel I (2018) Self-Repair of Structure and Bioactivity in a Supramolecular Nanostructure. Nano Lett 18:6832-6841
Du, Jingshan S; Chen, Peng-Cheng; Meckes, Brian et al. (2018) Windowless Observation of Evaporation-Induced Coarsening of Au-Pt Nanoparticles in Polymer Nanoreactors. J Am Chem Soc 140:7213-7221
Graves, Stephen; Seagle, Brandon-Luke L; Kocherginsky, Masha et al. (2018) Scholarship Support for Veterans Enrolling in MD, JD, and MBA Programs. JAMA 320:1197-1198

Showing the most recent 10 out of 1972 publications